display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced mGC or mGEJC
mGC or mGEJC - L1 - HER2 neg/PDL1 positivemGC or mGEJC - L1 - HER2 negativemGC or mGEJC - L1 - PDL1 positivemGC or mGEJC - L2 - all populationmGC or mGEJC - L2 - PDL1 positivemGC or mGEJC - M - HER2 negativemGC or mGEJC - M - HER2 neg/PDL1 positive
anti-PD-(L)1
avelumab based treatment
avelumab alone JAVELIN Gastric 300 JAVELIN Gastric 100 JAVELIN Gastric 100 ...
nivolumab based treatment
nivolumab alone ATTRACTION-2 ...
nivolumab plus SoC CheckMate 649 ... CheckMate 649 ... CheckMate 649
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-062 ... KEYNOTE-062 ... KEYNOTE-061 ... KEYNOTE-061 ...
pembrolizumab plus SoC KEYNOTE-062 ... KEYNOTE-062 ...

Study type: